LAGUNA HILLS, Calif., Dec. 10, 2025 /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced results from the first ...
A significant milestone in Ocugen's development of a gene therapy for Stargardt disease has triggered a substantial rally in the company's stock. The catalyst was the publication of positive Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback